Professor Paul Ruff has been Chief Specialist, Professor and Head of the Division of Medical Oncology of the Department of Medicine at the University of Witwatersrand Faculty of Health Sciences and Charlotte Maxeke Johannesburg Academic Hospital since 2002.
Professor Ruff runs the Medical Oncology Research Laboratory at the University of the Witwatersrand Faculty of Health Sciences with Dr Clement Penny. This laboratory studies metastasis and angiogenesis in gastrointestinal cancer, and has previously studied mutations in the oestrogen receptor and brca-1 and brca-2 genes in breast cancer.
In collaboration with the Wits Health Consortium Professor Ruff also runs the JHB ONCOLOGY Clinical Trial Unit performing clinical trials in hepatocellular carcinoma, colorectal cancer, gastric cancer, lung cancer, pancreatic cancer, breast cancer, renal cell cancer, carcinoma of the nasopharynx, chronic myeloid leukaemia, lymphomas as well as with antiemetic agents.
Professor Ruff serves on a number of committees appointed by the Minister of Health for the South African Department of Health, including the Medicines Control Council (MCC), the Clinical Trials Committee of the Medicines Control Council (MCC CTC), the Expert Committee on Tertiary/Quaternary Essential Medicines (EML Committee) and the Ministerial Advisory Committee on Cancer (MACC).
He is also chairman of the South African National Cancer Registry Scientific Advisory Committee and a past member of the Inaugural South African Bone Marrow Registry Management Board. He was also a member of the Cancer Association of South Africa Research Committee, and has held various posts in the South African Society of Medical Oncology, including its chairmanship from 2008 - 2013.
Professor Ruff was also appointed as one of two African representatives to the International Affairs Committee of the American Society of Clinical Oncology (ASCO IAC) in 2013.
Prof Ruff has authored or co-authored over 70 papers in peer-reviewed journals, recently including a number of landmark papers in the use of biological therapies in advanced colorectal cancer, as well as presenting over 140 papers and 45 posters at local and international scientific meetings.